Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It can reduce blood sugar via increasing the production of insulin. About two months ago in October, semaglutide was approved by FDA Advisory Committee as a new drug to treat type 2 diabetes.
As a GLP-1 analogue, semaglutide has the potential to impact the lives of people with type 2 diabetes by helping to meaningfully reduce A1c. Moreover, this treatment option may also have a weight-reducing effect. After careful discussions among the panel members regarding the efficacy and safety profile issues, semaglutide finally gained a unanimous 16-0 vote from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), which demonstrates the official approval of semaglutide for treating type 2 diabetes.
“The semaglutide is recommended to be used once-weekly in 2 therapeutic dosages: 0.5 mg and 1 mg,” says the leading scientist of the diabetes research team at BOC Sciences. “It should be administered once weekly via a dedicated prefilled pen device, on the same day each week, and can be taken any time of the day, with or without meals.”
About Type 2 Diabetes
For years, Type 2 diabetes has remained to be one of the greatest health concerns and entails huge costs economically. This disease is caused by increased insulin resistance coupled with progressive beta-cell failure. In recent years, glucagon-like peptide-1 receptor agonists (RAs) have gained increasing recognition for the treatment of type 2 diabetes. In clinical trials, GLP-1 RAs were associated with reductions in glycated haemoglobin (HbA1c), fasting plasma glucose and body weight, while at the same time, the most frequently observed side-effects are nausea, vomiting and diarrhea, etc.
About BOC Sciences
Though already well-established in the pharmaceutical industry, BOC Sciences never forgets its commitment of moving forward the great cause of drug discovery by providing premium chemical products and by making tailor-made services such as isotope labeling and chiral synthesis easily available. Now we are proud to say that we have very comprehensive CRO services spanning the entire molecule development pipeline, including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.
Media Contact
Company Name: BOC Sciences
Contact Person: Linna Green
Email: account@bocsci.com
Phone: 1-631-619-7922
Address:45-16 Ramsey Road
City: Shirley
State: NEW YORK
Country: United States
Website: http://www.bocsci.com